RT Journal Article
SR Electronic
T1 Treatment With Mifepristone Allows a Patient With End-stage Pancreatic Cancer in Hospice on a Morphine Drip to Restore a Decent Quality of Life
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 6997
OP 7001
DO 10.21873/anticanres.14724
VO 40
IS 12
A1 JEROME H. CHECK
A1 DIANE CHECK
A1 MAYA D. SRIVASTAVA
A1 TRINA PORETTA
A1 JAMES K. AIKINS
YR 2020
UL http://ar.iiarjournals.org/content/40/12/6997.abstract
AB Background: There is evidence that a unique immunomodulatory protein, known as the progesterone induced blocking factor (PIBF), is utilized by a large variety of cancers to escape immune surveillance. Mifepristone, a progesterone receptor antagonist/modulator, anecdotally, has been found to increase both length and quality of life in many different types of advanced cancers. Case Report: Though there was one previous case of pancreatic cancer that showed a significant reduction in pain for the one month she took mifepristone before changing to an experimental drug, the case presented here provided much greater evidence that this drug can markedly improve both length and quality of life, in at least some patients, with very advanced pancreatic cancer. Conclusion: It is hoped that this case report will influence others to prescribe mifepristone off-label and hopefully substantiate this finding of marked palliative benefit in the majority of a larger series of patients.